---
title: How to develop a Controlled Human Infection Model for Clostridioides difficile
date: '2024-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39214188/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240831181359&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Clostridioides difficile (C. difficile) remains the leading
  cause of healthcare-associated diarrhoea, posing treatment challenges due to antibiotic
  resistance and high relapse rates. Fecal microbiota transplantation (FMT) is a novel
  treatment strategy to prevent relapses of C. difficile infection (CDI), however
  the exact components conferring colonisation resistance are unknown, hampering its
  translation to a medicinal product. Development of novel products independent ...'
disable_comments: true
---
BACKGROUND: Clostridioides difficile (C. difficile) remains the leading cause of healthcare-associated diarrhoea, posing treatment challenges due to antibiotic resistance and high relapse rates. Fecal microbiota transplantation (FMT) is a novel treatment strategy to prevent relapses of C. difficile infection (CDI), however the exact components conferring colonisation resistance are unknown, hampering its translation to a medicinal product. Development of novel products independent ...